Terpenoid treatment in osteoporosis: this is where we have come in research. (November 2021)

• Record Type: Journal Article
• Authors: Bellavia, Daniele; Caradonna, Fabio; Dimarco, Eufrosina; Costa, Viviana; Carina, Valeria; De Luca, Angela; Raimondi, Lavinia; Gentile, Carla; Alessandro, Riccardo; Fini, Milena; Giavaresi, Gianluca
• Is Part Of: Trends in endocrinology and metabolism. Volume 32:Number 11(2021)
• Page Start: 846
• Page End: 861
• Publication Date: 2021-11
• Subjects: terpenoids -- osteoporosis -- osteoblast -- osteoclast -- bone erosive diseases; Endocrinology -- Periodicals; Metabolism -- Periodicals; Metabolism; 616.4
• DOI: 10.1016/j.tem.2021.07.011
• Languages: English
• ISSNs: 1043-2760

Abstract

Abstract : Lower bone resistance to load is due to the imbalance of bone homeostasis, where excessive bone resorption, compared with bone formation, determines a progressive osteopenia, leading to a high risk of fractures and consequent pain and functional limitations. Terpenoids, with their activities against bone resorption, have recently received increased attention from researchers. They are potentially more suitable for long-term use compared with traditional therapeutics. In this review of the literature of the past 5 years, we provide comprehensive information on terpenoids, with their anti-osteoporotic effects, highlighting molecular mechanisms that are often in epigenetic key and a possible pharmacological use in osteoporosis prevention and treatment. Highlights: Terpenoids act by promoting bone deposition and inhibiting bone resorption. Terpenoids reduce oxidative stress, determining bone deposition and reducing resorption, through regulation of bone tissue cells. Terpenoids act through several mechanisms, as epigenetic regulation through miRNAs and acetylase/deacetylases expression. Terpenoids have been proven to act on osteoclast differentiation and activities.